HighPoint Advisor Group LLC Lowers Position in Pfizer Inc. (NYSE:PFE)

HighPoint Advisor Group LLC decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 5.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 202,341 shares of the biopharmaceutical company’s stock after selling 10,819 shares during the period. HighPoint Advisor Group LLC’s holdings in Pfizer were worth $5,183,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. United Bank lifted its position in shares of Pfizer by 3.7% during the 3rd quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after buying an additional 1,277 shares in the last quarter. Fred Alger Management LLC lifted its holdings in Pfizer by 7.4% during the third quarter. Fred Alger Management LLC now owns 102,668 shares of the biopharmaceutical company’s stock worth $2,971,000 after acquiring an additional 7,076 shares during the period. Tradition Wealth Management LLC boosted its position in Pfizer by 4.5% in the third quarter. Tradition Wealth Management LLC now owns 25,358 shares of the biopharmaceutical company’s stock worth $734,000 after purchasing an additional 1,099 shares during the last quarter. Bellevue Group AG grew its stake in Pfizer by 59.2% in the 3rd quarter. Bellevue Group AG now owns 141,075 shares of the biopharmaceutical company’s stock valued at $4,083,000 after purchasing an additional 52,461 shares during the period. Finally, Semmax Financial Advisors Inc. increased its position in shares of Pfizer by 3.2% during the 3rd quarter. Semmax Financial Advisors Inc. now owns 101,267 shares of the biopharmaceutical company’s stock valued at $2,695,000 after purchasing an additional 3,185 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial lowered their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Finally, Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Up 0.8 %

Shares of PFE opened at $25.20 on Monday. The business’s 50-day moving average price is $26.06 and its 200-day moving average price is $26.90. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market cap of $142.93 billion, a PE ratio of 17.87, a P/E/G ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 EPS. On average, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.